search returned 100 results for adalimumab, showing results 81 to 90
of the current
PBS listing is sought
Note
Adalimumab Non-infectious
inflammatory uveitis
(including... on adalimumab for non-infectious intermediate, posterior or panuveitis done by Government
agencies... analysis has therefore shifted considerably. Adalimumab is a highly effective, evidence-
based
https://rheumatology.org.au/LinkClick.aspx?fileticket=t6BHxzbIa0c%3d
of the current
PBS listing is sought
Note
Adalimumab Non-infectious
inflammatory uveitis
(including... on adalimumab for non-infectious intermediate, posterior or panuveitis done by Government
agencies... analysis has therefore shifted considerably. Adalimumab is a highly effective, evidence-
based
https://rheumatology.org.au/LinkClick.aspx?fileticket=t6BHxzbIa0c%3d&portalid=2
review (see
agenda item 11)
• WR advised that he has drafted an evidence-based letter on adalimumab...
Agenda Item
13 March PBAC 2024 Meeting Agenda items to submit comments
• Adalimumab for vision... as biologic.
ACTIONS:
• As discussed above.
• WR to draft adalimumab for vision threatening
https://rheumatology.org.au/LinkClick.aspx?fileticket=aUV9ql38nnE%3d
review (see
agenda item 11)
• WR advised that he has drafted an evidence-based letter on adalimumab...
Agenda Item
13 March PBAC 2024 Meeting Agenda items to submit comments
• Adalimumab for vision... as biologic.
ACTIONS:
• As discussed above.
• WR to draft adalimumab for vision threatening
https://rheumatology.org.au/LinkClick.aspx?fileticket=aUV9ql38nnE%3d&portalid=2
as of 1 July
o Adalimumab is now PBS-listed for vision threatening non-infectious uveitis as of
1 Aug.
• Additionally, AbbVie has submitted a broad proposal for adalimumab in immune-
mediated... adalimumab for juvenile AS
o adalimumab for JIA.
TC Minutes 19 August 24 – Final Page 4
https://rheumatology.org.au/LinkClick.aspx?fileticket=t8oTnO66fBk%3d
Zealand
and had been stable on adalimumab for ankylosing spondylitis. Despite documentation
https://rheumatology.org.au/LinkClick.aspx?fileticket=QO8acjwmALo%3d
) is now listed on the PBS as an unrestricted benefit.
• Adalimumab is now TGA listed for the treatment
https://rheumatology.org.au/LinkClick.aspx?fileticket=3gsOPSUmbh4%3d
treatments with originator brands of abatacept, adalimumab,
baricitinib, certolizumab, etanercept
https://rheumatology.org.au/LinkClick.aspx?fileticket=Eq39UIB61Tc%3d
as of 1 July
o Adalimumab is now PBS-listed for vision threatening non-infectious uveitis as of
1 Aug.
• Additionally, AbbVie has submitted a broad proposal for adalimumab in immune-
mediated... adalimumab for juvenile AS
o adalimumab for JIA.
TC Minutes 19 August 24 – Final Page 4
https://rheumatology.org.au/LinkClick.aspx?fileticket=t8oTnO66fBk%3d&portalid=2
Zealand
and had been stable on adalimumab for ankylosing spondylitis. Despite documentation
https://rheumatology.org.au/LinkClick.aspx?fileticket=QO8acjwmALo%3d&portalid=2